STOP VARIANTS—The AstraZeneca vaccine is ineffective for mild and moderate #B1351 variant from South Africa 🇿🇦. Prior to Oct 31st (before B1351), 75% effective for non-B1351.

Luckily B1351 isn’t fast. We need to stop pandemic & new variants soon. #COVID19 nejm.org/doi/full/10.10…
2) Look at the efficacy yourself — it is incredibly low overall 10-20% and not significant (not distinguishable from 0%).

It was only 75% in early part of the trial before #B1351 emerged.
3) Lots of questions about vaccines versus Indian variant #B16172– we just don’t know yet.

But what I worry is if some of the bad variants mix together and do recombination inside of a co infected person with both variants/strains… that could be very bad.
4) Thus, based on the AstraZeneca vaccine and #B1351 results (peer reviewed randomized trial in NEJM no less) the chief of WHO Europe is wrong wrong wrong….
5) Reminder- there are many variants, and 4 key variants of concern… well 4 variant families because they India variant has the #B16172 that is most worrisome for its spread. I hope they don’t admix together and recombine together. That would be bad.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Eric Feigl-Ding

Eric Feigl-Ding Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrEricDing

22 May
TWO DOSES NEEDED—New UK vaccine data finds 1-shot protection for symptomatic infection of #B117 variant is 51%, and just 33% versus #B16172 from India. However, after 2 doses—87% for #B117 & 81% for #B16172. But mixed 3 vaccine types—unclear AZ vs mRNA. 🧵
ft.com/content/a70d42… Image
2) “This suggests a single shot offers 35 per cent less protection against B.1.617.2 compared with B.1.1.7, according to Financial Times analysis.
The PHE figures aggregate data from the BioNTech/Pfizer and Oxford/AstraZeneca jabs.”
3) “The rapid spread of B.1.617.2 in pockets of England has cast doubt on the country’s road map out of lockdown, with the next phase due to take place on June 21. “PHE scientists are evaluating the effectiveness of vaccines against B.1.617.2 variant” & will publish data later.
Read 8 tweets
22 May
Reopening schools in Texas potentially led to ~40,000 cases of #COVID19 and hundreds of deaths in Texas last year, study finds— “robust evidence that reopening Texas schools gradually but substantially accelerated the community spread of COVID-19." 🧵
abcnews.go.com/Health/rapid-s…
2) according to an analysis by economists and public policy experts from the University of Kentucky, analysis estimate that ~43,000 people contracted COVID-19 and 800 people possibly died in Texas two months after schools reopened statewide, when virus transmission was high.
3) The research highlights how in-person learning and its potential "spillover" can affect nearby communities.
Read 10 tweets
22 May
CDC needs to up its game:

“Forget ‘Stop the spread,’ you should be calling it ‘Stop the shrink!'”

HT @nbcsnl #COVID19 #CovidVaccine Image
2) new study—“two men following bouts with #COVID19 infections. 6-8 months afterwards, they still had virus particles in their penises. Not only that. They had developed severe erectile dysfunction (ED) even though they hadn’t had ED prior”. @bruce_y_lee
google.com/amp/s/www.forb…
3) “Examination found Covid-19 coronavirus particles near the blood vessel endothelial cells in the samples from the two patients who had had Covid-19. Blood vessel endothelial cells are cells lining the insides of the blood vessels in the penile tissue.”
Read 5 tweets
21 May
⚠️Whoa—Pfizer vaccine & #B16172 variant—the founder of BioNTech estimates their Pfizer vaccine to have a weakened efficacy of just 70-75% efficacy against B.1.617.2 variant (via India). A sizeable drop from 95%.

➡️CDC still wants to drop masks? #COVID19
globalnews.ca/video/rd/61f79… Image
2) To be clear, 70-75% efficacy still good, but it is nothing like 95%, and not enough to stop using masks. A weakened efficacy for a variant also suggests possible reinfection risk as well and likely more break through infections. This is no time to take off masks.
3) there is a good reason UK and WHO are concerned by the Indian origins #B16172 variant. It’s also poised to become the new dominant variant soon in UK
Read 5 tweets
21 May
HOSPITALIZATIONS increase again in parts of UK🇬🇧—The number of hospitalized #COVID19 patients in Bolton has increased, rising by 20% in 24 hours. Hospital opening an extra ward for Covid, as a previous ward is now full. Bolton hit by #B16172 variant.🧵
independent.co.uk/news/health/bo…
2) some weren’t sure if the Bolton UK rise was real or not. But with increasing hospitalizations—it’s now quickly becoming clear it’s real.
3) the surge in #B16172 variant from India in Bolton Uk seems especially hard in children. Schools in UK don’t mandate masks. Big mistake. Image
Read 5 tweets
21 May
📍Scientists have discovered a new canine coronavirus in a child who was hospitalized with pneumonia in 2018. If confirmed to be a human pathogen, it’d only be the world’s 8th coronavirus, and the first canine coronavirus, known to cause disease in humans.
nytimes.com/2021/05/20/hea… Image
2) It is not yet clear whether this specific virus poses a serious threat to humans, the researchers stress. The study does not prove that the pneumonia was caused by the virus, which may not be capable of spreading between people.
3) But the finding, which was published on Thursday in the journal Clinical Infectious Diseases, highlights the need to more proactively search for viruses that could jump from animals into humans, the scientists said.
Read 14 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(